Zanubrutinib Associated With Better Quality of Life Vs Bendamustine/Rituximab in CLL/SLLJuly 3rd 2022
Investigators have identified that zanubrutinib may improve the subpar health-related quality of life for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLLJune 30th 2022
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCLJune 26th 2022
Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.
Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-ThalassemiaJune 24th 2022
Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.
Pediatric/Young Adult Patients With B-ALL Continue to Derive Benefit From Tisagenlecluecel at 5-Year Follow-UpJune 22nd 2022
Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.
Blinatumomab: New Standard of Care for Pediatric, High-Risk ALLSeptember 6th 2020
Blinatumomab (Blincyto) monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant (HSCT) resulted a significant improvement in event-free survival (EFS) and a lower risk of recurrence in children with high-risk B-cell precursor (BCP­)–acute lymphoblastic leukemia (ALL).